Search Result

Isoforms Recommended:	ErbB3/HER3

Results for "

her3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (30) ADC Antibody (2) ADC Payload (1) Akt (7) Antibody-Drug Conjugates (ADCs) (3) Apoptosis (6) c-Met/HGFR (1) Carboxypeptidase (1) Caspase (1) CXCR (6) Drug-Linker Conjugates for ADC (3) ERK (3) Histamine Receptor (6) Isotope-Labeled Compounds (3) Ligands for Target Protein for PROTAC (3) mTOR (1) p38 MAPK (2) PARP (2) PD-1/PD-L1 (1) PI3K (3) PROTACs (2) Ras (1) Reference Standards (3) Small Interfering RNA (siRNA) (2) Survivin (1) Topoisomerase (2) VEGFR (1)
By Research Areas:	Cancer (37) Endocrinology (2) Infection (1) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	Azide (1)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: EGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99813

Patritumab deruxtecan her3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P99507

Zenocutuzumab MCLA-128; PB4188; R040517	EGFR	Cancer
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of *HER2* and *HER3* .

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to *ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-164702

BL-B01D1 Izalontamab Brengitecan	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
BL-B01D1 is a bispecific ADC, which targets EGFR and HER3 through bispecific antibody Izalontamab (HY-P99676), and exhibits cytotoxicity against various cancer cells via inhibition of DNA replication and DNA synthesis by its ADC toxin ED04 (HY-153891). BL-B01D1 can be used in the study of cancer .

HY-P99676

Izalontamab SI-B001; BL-B01D1 Antibody	EGFR	Cancer
Izalontamab (SI-B001) is a bispecific *anti-EGFR/HER3* monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-100848

TX1-85-1 2 Publications Verification	EGFR	Cancer
TX1-85-1 is an irreversible **Her3 (ErbB3) inhibitor with an IC₅₀** of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling .

HY-P991097

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets *HER3*. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99936

Elgemtumab LJM716	EGFR	Cancer
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .

HY-157813

2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan is a drug-linker conjugates for ADC, consiting of a cleavable linker and Exatecan (HY-13631). 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan can be linked to anti-Her3 antibody .

HY-141676

HyT36	EGFR	Others
HyT36 is a low molecular weight hydrophobic tag that promotes the degradation of fusion protein and pseudokinase *Her3* ^[3].

HY-P99866

Duligotuzumab MEHD-7945A; RG 7597	EGFR	Cancer
Duligotuzumab is a humanized IgG-κ monoclonal antibody targeting EGFR and *HER3. It blocks the binding of ligands to these two receptors, inhibits the downstream HER*/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cell-mediated cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes cell apoptosis, exerts a radiosensitizing effect, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research ^[3].

HY-P99304

Lumretuzumab Anti-Human ERBB3 Recombinant Antibody	EGFR PI3K Akt p38 MAPK	Cancer
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 *(ERBB3)* monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as *PI3K/AKT* and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .

HY-153796

*PROTAC Her3* Degrader-8**	PROTACs EGFR	Cancer
PROTAC Her3 Degrader-8 (Compound PP2) is a *Her3* PROTAC degrader. PROTAC Her3 Degrader-8 promotes the ubiquitination and degradation of Her3. PROTAC Her3 Degrader-8 can be used in the study of lung adenocarcinoma and ovarian cancer (Pink: Her3 ligand (HY-107450); Blue: E3 ligase ligand (HY-170861); Black: linker (HY-Y1760)) .

HY-178836

Z56-L23	Drug-Linker Conjugates for ADC Ras	Cancer
Z56-L23 is a conjugate of RAS-targeting ADC cytotoxic payload-linker with anti-tumor activity. Z56-L23 can be conjugated with *HER3* antibody, EGFR antibody or *EGFRxHER3* bispecific antibody to form intact antibody-drug conjugates (ADCs). ADC molecules related to Z56-L23 effectively inhibit the proliferation of tumor cells and also significantly suppress tumor growth in xenograft mouse models. Z56-L23 can be used in the research of pancreatic cancer .

HY-177760

PrCP-7414	Carboxypeptidase Apoptosis Akt	Cancer
PrCP-7414 is a prolyl carboxypeptidase (PRCP) inhibitor. PrCP-7414 blocks PRCP-mediated activation of the *IGF1R/HER3* signaling pathway and subsequent AKT activation. PrCP-7414 exhibits pro-apoptotic, anti-tumor and synergistic cytotoxic activities, and inhibits the proliferation and survival of triple-negative breast cancer cells. PrCP-7414 can be used for the research of breast cancer .

HY-B0426A

Olopatadine hydrochloride ALO4943A; KW4679	Histamine Receptor CXCR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

HY-P991237

Nezutatug HMBD-001	EGFR	Cancer
Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting *HER3. Nezutatug inhibits the dimerization of HER3* and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .

HY-111553

TAS0728	EGFR	Cancer
TAS0728 is a potent, selective, orally active, irreversible and covalent-binding *HER2* inhibitor, with an IC₅₀ of 13 nM. TAS0728 also shows IC₅₀s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for *BMX、HER4、BLK、EGFR、JAK3、SLK* and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of *HER2, HER3*, and downstream effectors .

HY-W062109

Olopatadine	Histamine Receptor CXCR	Inflammation/Immunology
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

HY-118998

TX2-121-1	PROTACs EGFR ERK Akt	Cancer
TX2-121-1 is a potent and selective **Her3 (ErbB3) degrader that contains a hydrophobic adamantane moiety. TX2-121-1 has an IC₅₀** of 49 nM for Her3. TX2-121-1 inhibits Her3-dependent signaling and heterodimerization of Her3. TX2-121-1 has the ability to inhibit cell proliferation. TX2-121-1 can be used in the study of tumors. (Pink: Her3 inhibitor (HY-164988); Black: Linker; Blue: Adamantane (HY-N2427)) .

HY-107444

*PROTAC Her3-binding moiety 1*	Ligands for Target Protein for PROTAC	Cancer
PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC .

HY-171747

AMT-562	Antibody-Drug Conjugates (ADCs) EGFR Topoisomerase Apoptosis	Cancer
AMT-562 is an antibody-drug conjugate (ADC) consisting of a novel anti-HER3 antibody Ab562 (HY-P991505) conjugated to the linker MC-VA-PAB and the topoisomerase I inhibitor Exatecan (HY-13631). The ADC toxic molecule and linker portion are MC-VA-PAB-Exatecan (HY-147270). AMT-562 can induce apoptosis and has antitumor activity against pancreatic, esophageal, and gastric cancers .

HY-107450

*PROTAC Her3-binding moiety 2*	Ligands for Target Protein for PROTAC EGFR	Cancer
PROTAC Her3-binding moiety 2 is a *Her3* inhibitor. PROTAC Her3-binding moiety 2 can be used for synthesis of PROTAC Her3 Degrader-8 (HY-153796) .

HY-P991505

*Anti-HER3* Antibody (Ab562)** AMT-562 antibody	ADC Antibody EGFR	Cancer
Anti-HER3 Antibody (Ab562) is an anti-HER3 monoclonal antibody. Anti-HER3 Antibody (Ab562) can be used to synthesize the antibody-drug conjugate (ADC) AMT-562 (HY-171747) .

HY-P991234

COVA208	EGFR p38 MAPK PI3K Akt	Cancer
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets *HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT* and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer .

HY-172091

CZY43	EGFR	Cancer
CZY43 is a *HER3* degrader. CZY43 can effectively induce HER3 degradation in a dose- and time-dependent manner in breast cancer SKBR3 cells. CZY43 potently inhibits HER3-dependent signaling and cancer cell growth and outperforms Bosutinib (HY-10158) .

HY-P991245

*Anti-ERBB3/HER3* (SGP1)**	EGFR	Cancer
Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting *ERBB3/HER3. Anti-ERBB3/HER3* (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .

HY-P991241

*Anti-ERBB3/HER3* (29Z6)**	EGFR	Cancer
Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor, targeting to human ERBB3/HER3.

HY-W062109S

Olopatadine-d6	Isotope-Labeled Compounds Histamine Receptor CXCR	Inflammation/Immunology
Olopatadine-d₆ is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

HY-164988

TX2-120-1	EGFR	Cancer
TX2-120-1 possesses the ability to bind to *Her3, with an IC₅₀* value of 56 nM for *Her3*. TX2-120-1 can be used for the synthesis of TX2-121-1 (HY-118998) .

HY-158016

Antiproliferative agent-49	EGFR Apoptosis	Cancer
Antiproliferative agent-49 (Compound 5a) is a EGFR-TK inhibitor with an IC₅₀ of 0.09 μM. Antiproliferative agent-49 is a anti-proliferative agent. Antiproliferative agent-49 displays good activities against *HER3* and *HER4* with IC₅₀ values 0.18 and 0.37 µM. Antiproliferative agent-49 induces mitochondrial apoptotic pathway and increased accumulation of ROS .

HY-107444R

*PROTAC Her3-binding moiety 1 (Standard)*	Reference Standards Ligands for Target Protein for PROTAC	Cancer
PROTAC Her3-binding moiety 1 (Standard) is the analytical standard of PROTAC Her3-binding moiety 1 (HY-107444). This product is intended for research and analytical applications. PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC .

HY-B0426AS

Olopatadine-d3 hydrochloride	Isotope-Labeled Compounds Histamine Receptor CXCR	Inflammation/Immunology Endocrinology
Olopatadine-d₃ hydrochloride (ALO4943A-d₃) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

HY-B0426AR

Olopatadine hydrochloride (Standard) ALO4943A (Standard); KW4679 (Standard)	Reference Standards Histamine Receptor CXCR	Inflammation/Immunology Endocrinology
Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3] .

HY-P991983

DB-1310 Antibody	ADC Antibody	Cancer
DB-1310 Antibody is a monoclonal antibody inhibitor targeting *HER3. DB-1310 Antibody can be used to synthesize the antibody-drug conjugate (ADC) DB-1310. DB-1310 Antibody is applicable to research related to HER3-positive* solid tumors, non-small cell lung cancer, breast cancer, colon cancer and prostate cancer .

HY-100848R

TX1-85-1 (Standard)	EGFR Reference Standards	Cancer
TX1-85-1 (Standard) is the analytical standard of TX1-85-1 (HY-100848). This product is intended for research and analytical applications. TX1-85-1 is an irreversible Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling .

HY-P991984

SIBP-03	EGFR PI3K Akt	Cancer
SIBP-03 is a specifical anti-HER3 antibody. SIBP-03 binds strongly and specifically to recombinant HER3 protein. SIBP-03 inhibits HER3 activation, as well as the downstream *PI3K/AKT* signaling pathway. SIBP-03 exhibits anticancer activity against squamous cell carcinoma, non-small cell lung cancer, gastric cancer, and breast cancer. SIBP-03 synergistically enhances the antitumor activity of DS-8201 (HY-138298A) and Cetuximab (HY-P9905) .

HY-P992103

Beruzatatug BNT326/YL202 Antibody	ADC Payload	Cancer
Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonal antibody against *HER3*. Beruzatatug can be used for the synthesis of ADCs, such as BNT326/YL202 .

HY-P992128

Rinumafusp alfa	EGFR	Others
Rinumafusp alfa is a human monoclonal antibody targeting *ERBB3/HER3*. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-RS04470

Erbb3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) EGFR	Others
Erbb3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Erbb3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Erbb3 Mouse Pre-designed siRNA Set A Erbb3 Mouse Pre-designed siRNA Set A

HY-P11757

Cyclo[K(N3)larllt]	EGFR	Cancer
Cyclo[K(N3)larllt] is a seven-membered cyclic peptide targeting EGFR, with a K_d value of 5.09 μM, and exhibits binding selectivity toward homologous proteins *HER2* and *HER3. Cyclo[K(N3)larllt] has no cytotoxicity and shows no growth inhibitory effect on cancer cells overexpressing EGFR. Cyclo[K(N3)larllt] can serve as a ligand for EGFR-targeted fluorescent conjugates, which is applicable to the detection of cancers with EGFR overexpression. Cyclo[K(N3)larllt*] can be used in the research of colorectal cancer .

HY-RS04469

ERBB3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) EGFR	Others
ERBB3 Human Pre-designed siRNA Set A contains three designed siRNAs for ERBB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ERBB3 Human Pre-designed siRNA Set A ERBB3 Human Pre-designed siRNA Set A

HY-150108

RMC-4745	mTOR Apoptosis Caspase	Cancer
RMC-4745 is a selective dual-site inhibitor of mTORC1, with a selectivity of 35 times for mTORC1 and mTORC2. RMC-4745 inhibits the proliferation of MCF-7 cells and upregulates *Caspase-3/7* activity to induce cell apoptosis. RMC-4745 does not cause the upregulation of HER3 due to the inhibition of mTORC2. RMC-4745 can be used for the study of breast cancer .

HY-177953

Mal-PEG2-Val-Arg-PABC-OMe-Eribulin	Drug-Linker Conjugates for ADC c-Met/HGFR	Cancer
Mal-PEG2-Val-Arg-PABC-OMe-Eribulin (Compound L-1) is a drug-linker conjugate composed of O-Me Eribulin (HY-159576) and the linker Mal-PEG2-Val-Cit-PAB-OH (HY-130222). Mal-PEG2-Val-Arg-PABC-OMe-Eribulin can be used to synthesize *anti-HER3/MET* antibody-drug conjugates (ADCs) .

HY-B0426AS2

Olopatadine-d6 hydrochloride ALO4943A-d6 hydrochloride; KW4679-d6 hydrochloride	Isotope-Labeled Compounds Histamine Receptor CXCR	Inflammation/Immunology
Olopatadine-d₆ (ALO4943A-d₆; KW4679-d₆) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

HY-P991977

BSI-001 5G9	EGFR Apoptosis PARP Akt ERK	Cancer
BSI-001 (5G9) is a *HER2*-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, *HER3, AKT* and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of *HER2*-positive breast cancer and *HER2*-overexpressing gastric cancer .

Cat. No.	Product Name	Type

HY-164702

BL-B01D1 Izalontamab Brengitecan	Fluorescent Dye
BL-B01D1 is a bispecific ADC, which targets EGFR and HER3 through bispecific antibody Izalontamab (HY-P99676), and exhibits cytotoxicity against various cancer cells via inhibition of DNA replication and DNA synthesis by its ADC toxin ED04 (HY-153891). BL-B01D1 can be used in the study of cancer .

HY-171747

AMT-562	Fluorescent Dye
AMT-562 is an antibody-drug conjugate (ADC) consisting of a novel anti-HER3 antibody Ab562 (HY-P991505) conjugated to the linker MC-VA-PAB and the topoisomerase I inhibitor Exatecan (HY-13631). The ADC toxic molecule and linker portion are MC-VA-PAB-Exatecan (HY-147270). AMT-562 can induce apoptosis and has antitumor activity against pancreatic, esophageal, and gastric cancers .

Cat. No.	Product Name	Target	Research Area

HY-P11757

Cyclo[K(N3)larllt]	EGFR	Cancer
Cyclo[K(N3)larllt] is a seven-membered cyclic peptide targeting EGFR, with a K_d value of 5.09 μM, and exhibits binding selectivity toward homologous proteins *HER2* and *HER3. Cyclo[K(N3)larllt] has no cytotoxicity and shows no growth inhibitory effect on cancer cells overexpressing EGFR. Cyclo[K(N3)larllt] can serve as a ligand for EGFR-targeted fluorescent conjugates, which is applicable to the detection of cancers with EGFR overexpression. Cyclo[K(N3)larllt*] can be used in the research of colorectal cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99507

Zenocutuzumab MCLA-128; PB4188; R040517	EGFR	Cancer
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of *HER2* and *HER3* .

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to *ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99676

Izalontamab SI-B001; BL-B01D1 Antibody	EGFR	Cancer
Izalontamab (SI-B001) is a bispecific *anti-EGFR/HER3* monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-P991097

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets *HER3*. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99936

Elgemtumab LJM716	EGFR	Cancer
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .

HY-P99866

Duligotuzumab MEHD-7945A; RG 7597	EGFR	Cancer
Duligotuzumab is a humanized IgG-κ monoclonal antibody targeting EGFR and *HER3. It blocks the binding of ligands to these two receptors, inhibits the downstream HER*/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cell-mediated cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes cell apoptosis, exerts a radiosensitizing effect, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research ^[3].

HY-P99304

Lumretuzumab Anti-Human ERBB3 Recombinant Antibody	EGFR PI3K Akt p38 MAPK	Cancer
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 *(ERBB3)* monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as *PI3K/AKT* and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .

HY-P991237

Nezutatug HMBD-001	EGFR	Cancer
Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting *HER3. Nezutatug inhibits the dimerization of HER3* and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .

HY-P991505

*Anti-HER3* Antibody (Ab562)** AMT-562 antibody	ADC Antibody EGFR	Cancer
Anti-HER3 Antibody (Ab562) is an anti-HER3 monoclonal antibody. Anti-HER3 Antibody (Ab562) can be used to synthesize the antibody-drug conjugate (ADC) AMT-562 (HY-171747) .

HY-P991234

COVA208	EGFR p38 MAPK PI3K Akt	Cancer
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets *HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT* and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer .

HY-P991245

*Anti-ERBB3/HER3* (SGP1)**	EGFR	Cancer
Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting *ERBB3/HER3. Anti-ERBB3/HER3* (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .

HY-P991241

*Anti-ERBB3/HER3* (29Z6)**	EGFR	Cancer
Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor, targeting to human ERBB3/HER3.

HY-P991983

DB-1310 Antibody	ADC Antibody	Cancer
DB-1310 Antibody is a monoclonal antibody inhibitor targeting *HER3. DB-1310 Antibody can be used to synthesize the antibody-drug conjugate (ADC) DB-1310. DB-1310 Antibody is applicable to research related to HER3-positive* solid tumors, non-small cell lung cancer, breast cancer, colon cancer and prostate cancer .

HY-P991984

SIBP-03	EGFR PI3K Akt	Cancer
SIBP-03 is a specifical anti-HER3 antibody. SIBP-03 binds strongly and specifically to recombinant HER3 protein. SIBP-03 inhibits HER3 activation, as well as the downstream *PI3K/AKT* signaling pathway. SIBP-03 exhibits anticancer activity against squamous cell carcinoma, non-small cell lung cancer, gastric cancer, and breast cancer. SIBP-03 synergistically enhances the antitumor activity of DS-8201 (HY-138298A) and Cetuximab (HY-P9905) .

HY-P992103

Beruzatatug BNT326/YL202 Antibody	ADC Payload	Cancer
Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonal antibody against *HER3*. Beruzatatug can be used for the synthesis of ADCs, such as BNT326/YL202 .

HY-P992128

Rinumafusp alfa	EGFR	Others
Rinumafusp alfa is a human monoclonal antibody targeting *ERBB3/HER3*. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991977

BSI-001 5G9	EGFR Apoptosis PARP Akt ERK	Cancer
BSI-001 (5G9) is a *HER2*-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, *HER3, AKT* and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of *HER2*-positive breast cancer and *HER2*-overexpressing gastric cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0426A

Olopatadine hydrochloride ALO4943A; KW4679	Structural Classification Alkaloids Classification of Application Fields Ketones, Aldehydes, Acids Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Histamine Receptor CXCR
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

HY-W062109

Olopatadine	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Histamine Receptor CXCR
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

HY-B0426AR

Olopatadine hydrochloride (Standard) ALO4943A (Standard); KW4679 (Standard)	Structural Classification Alkaloids Ketones, Aldehydes, Acids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Histamine Receptor CXCR
Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3] .

Species:	Human (10) Rhesus Macaque (3) Rat (2) Mouse (1)
Tag:	His (9) Tag Free (1) Avi (2) GST (1) Fc (6)
Source:	HEK293 (15) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P76967

	HER3 Protein, Rhesus Macaque (HEK293) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Rhesus Macaque	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Rhesus Macaque (HEK293) is the recombinant Rhesus Macaque-derived HER3 protein, expressed by HEK293 , with tag free.

HY-P70857

	HER3 Protein, Mouse (HEK293, His) Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3; ERBB3; her3	Mouse	HEK293
	HER3 Protein, a vital tyrosine-protein kinase and neuregulin cell surface receptor, activates upon binding to neuregulin-1 (NRG1), enhancing phosphorylation on tyrosine residues and associating with the p85 subunit of phosphatidylinositol 3-kinase. It is also activated by CSPG5 and plays a crucial role in regulating myeloid cell differentiation. HER3 Protein, Mouse (HEK293, His) is the recombinant mouse-derived HER3 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P76968

	HER3 Protein, Rhesus Macaque (HEK293, Fc) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Rhesus Macaque	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived HER3 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P76969

	HER3 Protein, Rhesus Macaque (HEK293, His) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Rhesus Macaque	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived HER3 protein, expressed by HEK293 , with C-His labeled tag.

HY-P704661

	HER3 Protein, Human (HEK293, mFc) rHuReceptor tyrosine-protein kinase erbB-3/her3, Fc; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3; ERBB3; her3	Human	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Human (HEK293, mFc) is the recombinant human-derived HER3 protein, expressed by HEK293, with C-mFc labeled tag.

HY-P70322

	HER3 Protein, Human (HEK293, Fc) 1 Publications Verification rHuReceptor tyrosine-protein kinase erbB-3/her3, Fc; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3; ERBB3; her3	Human	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Human (HEK293, Fc) is the recombinant human-derived HER3 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P70323

	HER3 Protein, Human (312a.a, HEK293, Fc) rHuReceptor tyrosine-protein kinase erbB-3/her3-312AA, Fc; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3; ERBB3; her3	Human	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Human (312a.a, HEK293, Fc) is the recombinant human-derived HER3 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P74891

	HER3 Protein, Rat (HEK293, His) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Rat	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Rat (HEK293, His) is the recombinant rat-derived HER3 protein, expressed by HEK293 , with C-His labeled tag.

HY-P74892

	HER3 Protein, Rat (HEK293, Fc) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Rat	HEK293
	HER3 is a tyrosine-protein kinase that is a key cell surface receptor for neuregulin. ErbB2 and ErbB3 can form dimers and activate signaling pathways including MAPK, PI3K/Akt and PLC纬 to promote tumor development. HER3 Protein, Rat (HEK293, Fc) is the recombinant rat-derived HER3 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P74894

	HER3 Protein, Human (Biotinylated, HEK293, Fc) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Human	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Human (Biotinylated, HEK293, Fc) is the recombinant human-derived HER3, expressed by HEK293, with C-hFc labeled tag.

HY-P74893

	HER3 Protein, Human (sf9, His-GST) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Human	Sf9 insect cells
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Human (sf9, His-GST) is the recombinant human-derived HER3 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P77554

	HER3 Protein, Human (Biotinylated, HEK293, His) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Human	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived HER3 protein, expressed by HEK293 , with C-His labeled tag.

HY-P72625

	HER3 Protein, Human (HEK293, His) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Human	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Human (HEK293, His) is the recombinant human-derived HER3 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72625A

	HER3 Protein, Human (HEK293, His, solution) Receptor tyrosine-protein kinase erbB-3; ERBB3; her3	Human	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Human (HEK293, His, solution) is the recombinant human-derived HER3 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72375

	HER3 Protein, Human (Biotinylated, HEK293, His-Avi) Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3; ERBB3	Human	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. HER3 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived HER3 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P701281

	*FITC-labeled HER3* Protein, Human (HEK293, His-Avi)** ERBB3; her3; LCCS2; MDA-BF-1; MGC88033; c-erbB3; erbB3-S; p180-ErbB3; p45-sErbB3; p85-sErbB3	Human	HEK293
	HER3, a pivotal tyrosine-protein kinase, acts as a crucial cell receptor for neuregulins. Neuregulin-1 (NRG1) activation boosts tyrosine phosphorylation and interaction with p85 subunit of phosphatidylinositol 3-kinase. CSPG5 may also activate HER3. Its involvement in myeloid cell differentiation underscores HER3's vital role in essential cellular processes for normal development and function. FITC-labeled HER3 Protein, Human (HEK293, His) is the recombinant human-derived FITC-labeled HER3 protein, expressed by HEK293 , with C-His, C-Avi labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W062109S

Olopatadine-d6

Olopatadine-d₆ is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

HY-B0426AS

Olopatadine-d3 hydrochloride

Olopatadine-d₃ hydrochloride (ALO4943A-d₃) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

HY-B0426AS2

Olopatadine-d6 hydrochloride

Olopatadine-d₆ (ALO4943A-d₆; KW4679-d₆) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis ^[3].

Host:	Mouse (2) Rabbit (5)
Reactivity:	Human (7) Rat (1) Mouse (3)
Application:	IHC-P (3) ICC/IF (4) IP (1) WB (7) FC (2) ELISA (3)
Isotype:	IgG (5) IgG1 (2)
Conjugation:	Non-conjugated (7) Biotin (3)
Clonality:	Monoclonal (2) Monoclonal Antibody (1) Recombinant (1)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84183

	*C-erbB-3/HER3* Antibody (YA3880)** her3; c-erbB3	WB, ICC/IF, ELISA	Human
	C-erbB-3/HER3 Antibody (YA3880) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C-erbB-3/HER3.

HY-P84183A

	*C-erbB-3/HER3* Antibody (YA3880)(PBS only)** her3; c-erbB3	WB, ICC/IF, ELISA	Human
	C-erbB-3/HER3 Antibody (YA3880) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C-erbB-3/HER3.

HY-P86321

	*C-erbB-3/HER3* Antibody (YA6013)** ERBB3; her3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	C-erbB-3/HER3 Antibody (YA6013) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-3/HER3.

HY-P80659

	*C-erbB-3/HER3* Antibody (YA457)** ERBB3; her3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3	WB, IHC-P, FC	Human, Mouse
	C-erbB-3/HER3 Antibody (YA457) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-3/HER3.

HY-P80659A

	*C-erbB-3/HER3* Antibody (YA457)(PBS only)** ERBB3; her3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3	WB, IHC-P, FC	Human, Mouse
	C-erbB-3/HER3 Antibody (YA457) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C-erbB-3/HER3.

HY-P810612

	*Phospho-HER3/ErbB3 (Tyr1222) Antibody (YA9874)* ERBB3; her3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3	WB, IHC-P	Human
	Phospho-HER3/ErbB3 (Tyr1222) Antibody (YA9874) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-HER3/ErbB3 (Tyr1222).

HY-P810613

	*Phospho-ErbB3/HER3* (Tyr1289) Antibody (YA9875)** ERBB3; her3; Receptor tyrosine-protein kinase erbB-3; Proto-oncogene-like protein c-ErbB-3; Tyrosine kinase-type cell surface receptor her3	WB, ICC/IF	Human
	Phospho-ErbB3/HER3 (Tyr1289) Antibody (YA9875) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-ErbB3/HER3 (Tyr1289).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-P11757

Cyclo[K(N3)larllt]		Azide
Cyclo[K(N3)larllt] is a seven-membered cyclic peptide targeting EGFR, with a K_d value of 5.09 μM, and exhibits binding selectivity toward homologous proteins *HER2* and *HER3. Cyclo[K(N3)larllt] has no cytotoxicity and shows no growth inhibitory effect on cancer cells overexpressing EGFR. Cyclo[K(N3)larllt] can serve as a ligand for EGFR-targeted fluorescent conjugates, which is applicable to the detection of cancers with EGFR overexpression. Cyclo[K(N3)larllt*] can be used in the research of colorectal cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

her3

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products